Sydney, Australia, July 15, 2021 – The International Myopia Institute (IMI) is pleased to announce the release of the 2021 IMI White Papers Clinical Summaries in English and other languages.
The IMI recently published the highly anticipated second volume of the 2021 IMI White Papers and yearly digest in a special issue of the peer-reviewed Investigative Ophthalmology and Visual Science (IOVS) journal. We are excited to announce that the IMI clinical summaries of these white papers are now available both in English and up to twelve international languages including English, Chinese, Vietnamese, Turkish, Spanish, French, Russian, German and Dutch. The IMI clinical summaries serve to make the IMI’s groundbreaking evidence-based information in myopia management accessible to all eye-care practitioners (ECPs) around the world in easy-to-understand language and are one page in length. More than 134 world-leading experts in the field of myopia contributed to these white papers, which are utilised globally by the eye care profession and peak health bodies, providing updates to regions where the knowledge that we can prevent and slow myopia has not yet reached or remains in its infancy.
Executive Director IMI
“We are excited to continue to bring the latest, evidence-based information directly to all ECPs across the world, by making this information easily understandable and accessible, through working with our incredible taskforce leaders and teams, translators and industry supporters,” said IMI Executive Director, Dr Monica Jong.
The IMI White Papers are among the top 2% of cited work, driving discussion, informing policy, and progressively advancing research, patient management and education in myopia to prevent future vision impairment and blindness associated with increasing myopia.
The IMI white papers volume one and two and the latest clinical summaries in up to twelve international languages are available at myopiainstitute.org/imi-white-papers/.
ENDS
ABOUT THE INTERNATIONAL MYOPIA INSTITUTE
The International Myopia Institute was formed following the WHO-BHVI meeting on myopia and high myopia in 2015, due to the need to address the increasing levels of myopia and high myopia worldwide that can lead to potentially sight threatening complications for an individual, and the massive global burden associated with lost productivity.
The IMI is a global group of experts who have come together to discuss, debate and make available the latest evidence-based recommendations in classifications, patient management, and research, in the form of the IMI white papers.
Our mission is to advance research, patient management and education in myopia to prevent future vision impairment and blindness associated with increasing myopia. We aim to do this by bringing together, scientists, clinicians, policy makers, government and educators into the field of myopia to stimulate collaboration and sharing of knowledge.
Founded by Brien Holden Vision Institute (BHVI).
Supported by Zeiss, Essilor, CooperVision, Alcon and OCULUS.
